Amgen studying genes to target pain conditions
For the next year, Amgen and Boston Children’s Hospital will use genetic analysis to study pain sensitivity. The biotech giant based in Thousand Oaks will work with patients who have abnormal pain conditions, and the hospital will validate genetic markers as potential targets for new therapies, the two announced in a press release on Oct. 16. “Traditional Read More →
Read More →
Amgen settles with AbbVie over Humira biosimilar litigation
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Marian Regional Medical Center expands health care options
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Oak Therapeutics touts study results for dissolvable strips
Oak Therapeutics, based in Oxnard, announced that it completed a study of the use of its dissolvable strips to administer an anti-tuberculosis treatment orally. A 300 milligram dose of isoniazid on the dissolvable strips given to canines entered the bloodstream at a statistically similar rate to commercial tablets, the study found. The company, a subsidiary Read More →
Read More →Amgen lawsuit over cholesterol drug will get new trial
An Amgen lawsuit against a competing cholesterol drug will get a new trial but sales of the drug will be allowed in the U.S. until a decision is rendered. A federal court of appeals judge threw out a ban on the sale of Praluent, manufactured by New York-based Regeneron Pharmaceuticals and French biotech company Sanofi Read More →
Read More →Mannkind stock soars over new label info for Afrezza
Westlake Village biotech company Mannkind received approval to update the prescribing information for its inhalable insulin product, Afrezza, making it easier to market to customers. The new label information clarifies starting and adjusting mealtime dosages, as well as initial and peak effects, and helps the company avoid confusing language, CEO Michael Castagna said in a Read More →
Read More →Amgen settles with AbbVie over Humira biosimilar
Thousand Oaks biopharmaceutical giant Amgen announced Sept. 28 that it had reached a settlement with Chicago-based competitor AbbVie, which had sued to block Amgen’s Humira biosimilar Amjevita. The rheumatoid arthritis and inflammation treatment received U.S. Food and Drug Administration approval in September of 2016, but sales were blocked when AbbVie filed a patent infringement claim Read More →
Read More →
Home of the Week
Sponsored Listing
Reimagined Contemporary Mediterranean Home, Solvang
